|
1.
|
American Cancer Society: Cancer Facts and
Figures 2013. American Cancer Society; Atlanta, GA: 2013
|
|
2.
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar
|
|
3.
|
Cowgill SM and Muscarella P: The genetics
of pancreatic cancer. Am J Surg. 186:279–286. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Li D and Jiao L: Molecular epidemiology of
pancreatic cancer. Int J Gastrointest Cancer. 33:3–14. 2003.
View Article : Google Scholar
|
|
5.
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefic with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
6.
|
Cunningham D, Chau I, Stocken DD, et al:
Phase III randomized comparison of gemcitabine versus gemcitabine
plus capecitabine in patients with advanced pancreatic cancer. J
Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Conroy T, Desseigne F, Ychou M, et al:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Matthaios D, Zarogoulidis P, Balgouranidou
I, Chatzaki E and Kakolyris S: Molecular pathogenesis of pancreatic
cancer and clinical perspective. Oncology. 81:259–272. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Bryan HK, Olayanju A, Goldring CE and Park
BK: The Nrf2 cell defence pathway: Keap1-dependent and -independent
mechanisms of regulation. Biochem Pharmacol. 85:705–717. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Mitsuishi Y, Motohashi H and Yamamoto M:
The Keap1-Nrf2 system in cancers: stress response and anabolic
metabolism. Front Oncol. 2:2002012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ma Q: Role of Nrf2 in oxidative stress and
toxicity. Annu Rev Pharmacol Toxicol. 53:401–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Niture SK, Khatri R and Jaiswal AK:
Regulation of NRF2-an update. Free Radic Biol Med. View Article : Google Scholar : 2013.
|
|
13.
|
Kang HJ, Hong YB, Kim HJ and Bae I:
CR6-interacting factor 1 (CRIF1) regulates NF-E2-related factor 2
(NRF2) protein stability by proteasome-mediated degradation. J Biol
Chem. 285:21258–21268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Martín-Montalvo A, Villalba JM, Navas P
and de Cabo R: NRF2, cancer and calorie restriction. Oncogene.
30:505–520. 2011.PubMed/NCBI
|
|
15.
|
Hayes JD and McMahon M: NRF2 and KEAP1
mutations: permanent activation of an adaptive response in cancer.
Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
DeNicola GM, Karreth FA, Humpton TJ, et
al: Oncogene-induced Nrf2 transcription promotes ROS detoxification
and tumorigenesis. Nature. 475:106–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
et al: RNAi-mediated silencing of nuclear factor erythroid-2
related factor 2 gene expression in non-small cell lung cancer
inhibits tumor growth and increases efficacy of chemotherapy.
Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Yamadori T, Ishii Y, Homma S, et al:
Molecular mechanisms for the regulation of Nrf2-mediated cell
proliferation in non-small-cell lung cancers. Oncogene.
31:4568–4577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Homma S, Ishii Y, Morishima Y, et al: Nrf2
enhances cell proliferation and resistance to anticancer drugs in
human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hong YB, Kang HJ, Kwon SY, et al: Nuclear
factor (erythroid-derived 2)-like 2 regulates drug resistance in
pancreatic cancer cells. Pancreas. 39:463–472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Lister A, Nedjadi T, Kitteringham NR, et
al: Nrf2 is overexpressed in pancreatic cancer: implications for
cell proliferation and therapy. Mol Cancer. 10:372011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: the combined effects of
multiple drugs and enzyme inhibitors. Adv Enz Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Kang HJ, Kim HJ, Kim SK, et al: BRCA1
modulates xenobiotic stress-inducible gene expression by
interacting with ARNT in human breast cancer cells. J Biol Chem.
281:14654–14662. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kang HJ, Kim HJ, Rih JK, et al: BRCA1
plays a role in the hypoxic response by regulating HIF-1alpha
stability and by modulating vascular endothelial growth factor
expression. J Biol Chem. 281:13047–13056. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Duong HQ, Kim HJ, Kang HJ, Seong YS and
Bae I: ZSTK474, a PI3K inhibitor, suppresses proliferation and
sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Oncol Rep. 27:182–188. 2012.PubMed/NCBI
|
|
26.
|
Knight ZA, Gonzalez B, Feldman ME, et al:
A pharmacological map of the PI3-K family defines a role for p110α
in insulin signaling. Cell. 125:733–747. 2006.PubMed/NCBI
|
|
27.
|
Loboda A, Was H, Jozkowicz A and Dulak J:
Janus face of Nrf2-HO-1 axis in cancer - friend in chemoprevention,
foe in anticancer therapy. Lung Cancer. 60:1–3. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Kensler TW and Wakabayashi N: Nrf2: friend
or foe for chemoprevention? Carcinogenesis. 31:90–99. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Müller T and Hengstermann A: Nrf2: friend
and foe in preventing cigarette smoking-dependent lung disease.
Chem Res Toxicol. 25:1805–1824. 2012.PubMed/NCBI
|
|
30.
|
Sporn MB and Liby KT: NRF2 and cancer: the
good, the bad and the importance of context. Nat Rev Cancer.
12:564–571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Hayes JD, McMahon M, Chowdhry S and
Dinkova-Kostova AT: Cancer chemoprevention mechanisms mediated
through the Keap1-Nrf2 pathway. Antioxid Redox Signal.
13:1713–1748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Shelton P and Jaiswal AK: The
transcription factor NF-E2-related factor 2 (Nrf2): a
protooncogene? FASEB J. 27:414–423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Hur W and Gray NS: Small molecule
modulators of antioxidant response pathway. Curr Opin Chem Biol.
15:162–173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Yotsumoto F, Fukami T, Yagi H, et al:
Amphiregulin regulates the activation of ERK and Akt through
epidermal growth factor receptor and HER3 signals involved in the
progression of pancreatic cancer. Cancer Sci. 101:2351–2360. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Cartee L and Kucera GL: Gemcitabine
induces programmed cell death and activates protein kinase C in
BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol.
41:403–412. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Huynh H, Soo KC, Chow PK and Tran E:
Targeted inhibition of the extracellular signal-regulated kinase
kinase pathway with AZD6244 (ARRY-142886) in the treatment of
hepatocellular carcinoma. Mol Cancer Ther. 6:138–146. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Cross DA, Alessi DR, Cohen P, Andjelkovich
M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by
insulin mediated by protein kinase B. Nature. 378:785–789. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Srivastava AK and Pandey SK: Potential
mechanism(s) involved in the regulation of glycogen synthesis by
insulin. Mol Cell Biochem. 182:135–141. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Chowdhry S, Zhang Y, McMahon M, Sutherland
C, Cuadrado A and Hayes JD: Nrf2 is controlled by two distinct
β-TrCP recognition motifs in its Neh6 domain, one of which can be
modulated by GSK-3 activity. Oncogene. 32:3765–3781. 2013.
|
|
40.
|
Jain AK and Jaiswal AK: GSK-3β acts
upstream of Fyn kinase in regulation of nuclear export and
degradation of NF-E2 related factor 2. J Biol Chem.
282:16502–16510. 2007.
|
|
41.
|
Niture SK, Jain AK, Shelton PM and Jaiswal
AK: Src subfamily kinases regulate nuclear export and degradation
of transcription factor Nrf2 to switch off Nrf2-mediated
antioxidant activation of cytoprotective gene expression. J Biol
Chem. 286:28821–28832. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Niture SK, Jain AK and Jaiswal AK:
Antioxidant-induced modification of INrf2 cysteine 151 and
PKC-δ-mediated phosphorylation of Nrf2 serine 40 are both required
for stabilization and nuclear translocation of Nrf2 and increased
drug resistance. J Cell Sci. 122:4452–4464. 2009.PubMed/NCBI
|
|
43.
|
Donadelli M, Costanzo C, Beghelli S, et
al: Synergistic inhibition of pancreatic adenocarcinoma cell growth
by trichostatin A and gemcitabine. Biochim Biophys Acta.
1773:1095–1106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Duong HQ, Hong YB, Kim JS, et al:
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of
pancreatic adenocarcinoma cells to gemcitabine. J Cell Mol Med.
17:1261–1270. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Haimeur A, Conseil G, Deeley RG and Cole
SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins:
biology, substrate specificity and regulation. Curr Drug Metab.
5:21–53. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Dallas S, Schlichter L and Bendayan R:
Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflus of
9-(2-phosphonylmethoxyethyl)adenine by microglia. J Pharmacol Exp
Ther. 309:1221–1229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Hagmann W, Jesnowski R and Löhr JM:
Interdependence of gemcitabine treatment, transporter expression,
and resistance in human pancreatic carcinoma cells. Neoplasia.
12:740–747. 2010.PubMed/NCBI
|
|
48.
|
Oguri T, Achiwa H, Sato S, et al: The
determinants of sensitivity and acquired resistance to gemcitabine
differ in non-small cell lung cancer: a role of ABCC5 in
gemcitabine sensitivity. Mol Cancer Ther. 5:1800–1806. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Satoh H, Moriguchi T, Takai J, Ebina M and
Yamamoto M: Nrf2 prevents initiation but accelerates progression
through the Kras signaling pathway during lung carcinogenesis.
Cancer Res. 73:4158–4168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Arlt A, Sebens S, Krebs S, et al:
Inhibition of the Nrf2 transcription factor by the alkaloid
trigonelline renders pancreatic cancer cells more susceptible to
apoptosis through decreased proteasomal gene expression and
proteasome activity. Oncogene. 32:4825–4835. 2013. View Article : Google Scholar
|
